

1 Potential Test-Negative Case-Control Study Bias in Outbreak Settings:
2 Application to Ebola vaccination in Democratic Republic of Congo

3

4 Carl A. B. Pearson^{1,2,*}, W. John Edmunds¹, Thomas J. Hladish³, Rosalind M. Eggo¹

5 ¹Department of Infectious Disease Epidemiology & Centre for the Mathematical Modelling of
6 Infectious Diseases, London School of Hygiene & Tropical Medicine

7 ²South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University

8 ³Department of Biology & Emerging Pathogens Institute, University of Florida

9 *carl.pearson@lshtm.ac.uk

10

11 Abstract

12 Background

13 Infectious disease outbreaks present unique challenges to study designs for vaccine evaluation. Test-
14 negative case-control (TNCC) studies have been used to estimate vaccine efficacy previously, and
15 have been proposed for Ebola virus disease (EVD) vaccines. However, there are key differences in
16 how cases and controls are recruited during outbreaks that have implications for the reliability of
17 vaccine efficacy estimates from these studies.

18 Methods

19 We use a modelling approach to quantify TNCC bias for a prophylactic vaccine distributed across
20 varying study and epidemiological scenarios. Our model accounts for vaccine distribution
21 heterogeneity and for the two potential routes of recruitment: self-reporting and contact-tracing.
22 We derive the TNCC estimator for this model and suggest ways to translate outbreak response data
23 into the parameters of the model.

24 Results

25 We found systematic biases in vaccine estimates from a TNCC study in our model of outbreak
26 conditions. Biases are introduced due to differential recruitment from self-report and contact-
27 tracing, and by clustering of participation in vaccination. We estimate the magnitude of these biases,
28 and highlight options to manage them via restricted recruitment. For the motivating example of
29 EVD, the absolute bias should be less 10%.

30 Conclusions

31 A TNCC study may generate biased estimates of vaccine efficacy during outbreaks. Bias can be
32 limited via recruitment that either minimizes heterogeneity in vaccination in the recruited
33 population or excludes recruitment of contact-traced individuals. TNCC studies for outbreak
34 infections should record the reason for testing to quantify potential bias in the vaccine efficacy
35 estimate. Perfectly distinguishing the recruitment route may be difficult in practice, so it will be
36 challenging to entirely remove this bias.

37

38

39 Key Messages

- 40 - Test-Negative Case-Control (TNCC) studies can be biased when follow-up of cases leads to
41 recruitment, which may happen during outbreak response.
- 42 - The absolute bias can be quantified using epidemiological measures.
- 43 - Bias can be limited by ensuring homogeneous vaccine coverage amongst potential recruits.
- 44 - Bias can be eliminated if excluding recruits from contact-tracing is practical.
- 45 - Based on assumptions about the outbreak in Nord Kivu DRC starting in 2018, a TNCC vaccine
46 study there would have a maximum absolute bias of less than 10% due to these effects.

47

48 Background

49 Study designs to evaluate vaccine efficacy for new vaccines during outbreaks are challenging for
50 logistical, epidemiological, social, and ethical reasons (1-7). Outbreaks can overwhelm local health
51 systems, subsequently enabling other crises, complicating both response efforts and research (8-11).
52 However, some key pathogens are only routinely observable under these conditions, like Ebola virus
53 disease (EVD) and others on the World Health Organization (WHO) R&D Blueprint priority list (12).

54 During outbreaks of highly pathogenic infections there may be pressure to introduce experimental
55 vaccines as quickly as possible (13, 14), as well as resistance to classical randomised controlled trials
56 (15). For EVD, the existence of a licensed vaccine (16-19) further complicates trials for new vaccines.
57 Such circumstances require alternative evaluation strategies, and the test-negative case-control
58 (TNCC) design has been proposed to evaluate a two-dose vaccine in eastern Democratic Republic of
59 Congo (DRC) (20-22). This design estimates vaccine efficacy from the odds ratio for test outcome
60 conditional on vaccination status, and has lower misclassification bias than traditional case-control
61 studies (23, 24).

62 TNCC studies have been used estimate the efficacy of vaccines against influenza (25), rotavirus (26-
63 28), pneumococcus (29), and other pathogens (30, 31). The design can also assess interventions such
64 as vector control and risk-factor management (32-34). TNCC studies recruit people with symptoms,
65 test those recruits using a highly sensitive and specific method to separate cases (test-positives)
66 from controls (test-negatives), and finally sort them by vaccination status (35). These TNCC studies
67 can be retrospective, potentially using stratification by other factors to limit confounding. For
68 influenza, TNCC studies usually recruit people seeking care for influenza-like illness, ascertain
69 vaccine status by self-report, and determine infection status by RT-PCR, though specifics vary (25,
70 30).

71 To obtain unbiased estimates, the following criteria must be met: i) transmission occurs in a
72 population with partial vaccine coverage; ii) test-negative rates are unaffected by vaccination status;
73 iii) given symptoms in an individual, care-seeking behaviour does not vary by underlying cause; iv) an
74 individual's past recruitment as a control (even multiple times) must not prevent subsequent
75 recruitment as a case; and v) there is no misclassification of individuals' infection or vaccine status
76 (33, 36).

77 We examined how outbreaks present novel misclassification problems for TNCC studies, and how
78 this can bias TNCC vaccine efficacy estimates. We quantified how that bias varies with differences in
79 vaccine distribution, recruitment, risk of infection, and testing practice, and we identified steps to
80 mitigate this bias.

81 Methods

82 Key Differences During EVD Outbreaks

83 EVD tests are used both to make treatment decisions for individuals and to trigger public health
84 responses to the outbreak (*e.g.* post-mortem testing). During EVD outbreaks, suspect cases are
85 tested for distinct reasons: either presence of multiple symptoms or contact with a known case, plus
86 fever (37, 38). We treat these testing reasons as distinct recruiting sources: people who self-report
87 seeking care for EVD-like symptoms (analogous to influenza studies); and people identified via active
88 contact-tracing from a confirmed case. Depending on how data are collected, individual testing
89 reasons may be unavailable. For clarity, we provide specific definitions for our model terms (**Table 1**).

90 (**Table 1 here**).

91 Vaccination Model

92 Vaccinated individuals avoid infection if exposed to EVD with probability E , the true vaccine efficacy.
93 The study measures \hat{E} , the estimated vaccine efficacy. Vaccines may have further complications,
94 such as multiple doses or a delay to protection, but we model a scenario where protection has
95 already occurred in the recruitable population. Aside from preventing EVD, vaccination has no
96 effect.

97 We represent vaccine distribution by dividing the recruitable population into two types of
98 individuals: those who participate in the vaccination campaign and those who do not (Figure 1). They
99 are participating and non-participating (Table 1), and the fraction is p_{in} (Table 2). Among
100 participating individuals, only some receive the vaccine, leading to vaccine coverage level, L . We
101 assume individuals cluster by participation status, so the contacts of self-reporting cases always have
102 the same participation status as the associated case. Aside from these distinctions, all individuals are
103 identical.

104 Ideally, a study would recruit only participating individuals, but they may not be distinguishable in
105 practice. Indeed, in reality there may be many distinct populations, for example areas with different
106 vaccination coverage; we consider just two to focus on the impact of heterogeneity.

107 TNCC Recruitment Model

108 We identify recruits by their testing route, either self-reported or contact-traced from a confirmed
109 case (Table 1 and Figure 1). In the Supplement, we generalise these as *primary* and *secondary*
110 recruitment routes. We assume that introduced cases in the recruitable population are found before
111 any contacts have become symptomatic and therefore infectious (though they may be infected but
112 not yet symptomatic), consistent with the typical experience in the rVSV trial in DRC (39). Thus, in
113 the model all self-reported cases result from external introductions, and all contact-traced recruits
114 are only exposed to a one case.

115 Consistent with the field alerts process, we model self-reporting as presenting with multiple EVD-like
116 symptoms caused either by EVD (a self-reported test-positive) or not (a self-reported test-negative).
117 Participating and non-participating individuals are assumed to have equal rates of EVD and non-EVD
118 exposure, but on average participating individuals have fewer EVD infections due to the vaccine.
119 During an outbreak, EVD and non-EVD exposure rates may vary, but our analysis only depends on
120 the long-term average relative rate of these processes. We can then define parameters as per self-
121 reported test-positive, and we use the background self-reporting test-negatives per test-positive
122 rate, B , to represent the self-reporting process overall (Table 2).

123 We also represent contact-traced testing based on the field alerts process. Fever is common in EVD-
124 prone areas and we therefore assume that meeting this criterion and testing contacts is frequent.
125 The average number of tested contacts is λ , which is the same irrespective of EVD exposure or
126 participation status (Supplement Section S2.3 relaxes this assumption).

127 Translating outbreak metrics to estimate bias

128 To evaluate a particular study's potential bias, we need real-world outbreak response metrics to
129 estimate model parameters. For studies augmenting an ongoing outbreak response, data already
130 collected could be used. For example, data on the number of tested individuals, stratified by test
131 outcome and testing route could be used to bound model parameters (Table 2).

132 The model also depends on how the study vaccination is distributed, represented by participating
133 fraction and coverage, p_{in} and L . Depending on the study protocol, these could be ascertained in
134 different ways (Supplement Section S7).

135 Summary of assumptions

- 136 • Cases and their contacts have the same participation status.
- 137 • All individuals have the same exposure risk to EVD and other causes of EVD-like symptoms,
- 138 average number of contacts, and risk of infection per contact.
- 139 • Non-vaccination among participating individuals happens randomly.
- 140 • There are different testing criteria for self-reporting and contact-tracing individuals.
- 141 • Self-reporting cases are identified before anyone they have infected becomes symptomatic,
- 142 and contact tracing prevents transmission amongst contacts.

143 **(Table 2 here)**

144 **TNCC Estimator for Outbreak Context**

145 There are twelve recruitment categories in our model, based on participation and vaccination status,
146 test outcome, and testing route (Figure 1). The conventional TNCC estimator:

147
$$\text{estimated efficacy} = 1 - \frac{\# \text{ vaccinated, test-positive}}{\# \text{ unvaccinated, test-positive}} \times \frac{\# \text{ unvaccinated, test-negative}}{\# \text{ vaccinated, test-negative}}$$

148 can be written with these categories as:

149
$$\hat{E} = 1 - \frac{V'_+ + V''_+}{N'_+ + N''_+ + U'_+ + U''_+} \times \frac{N'_- + N''_- + U'_- + U''_-}{V'_- + V''_-} \quad (1)$$

150 with participation status by letter, testing route by superscript, and test outcome by subscript
151 (Figure 1). The expected counts of these categories can be expressed with the six model parameters
152 we defined (full derivation in Supplement S3-S4):

153
$$\hat{E} = 1 - (1 - E) \left[1 + \frac{ER''}{1+R''(1-LE)} \frac{L(1-p_{in})}{1-Lp_{in}} \right]^{-1} \frac{B + \left[1 + \frac{Lp_{in} LE(1-p_{in})}{1-Lp_{in} 1-LEp_{in}} \right] (\lambda - R'')}{B + \frac{1-LE}{1-LEp_{in}} (\lambda - R''(1-E))} \quad (2)$$

154 The terms to the right only cancel under very specific circumstances, thus the bias is generally non-
155 zero and the magnitude includes all model parameters. We refactor Eq. 2 with alternative
156 parameters relating to recruitment and epidemiological measures relating to the outbreak
157 (Supplement Section S4). We use this form to explore the bias and to evaluate potential maximum
158 bias under specific outbreak scenarios:

159
$$\hat{E} = 1 - (1 - E) \left[1 + \frac{E \frac{p_t \rho}{1-f_-}}{1 + \frac{p_t \rho}{1-f_-} (1-LE)} \frac{L(1-p_{in})}{1-Lp_{in}} \right]^{-1} \frac{1 + \left[1 + \frac{Lp_{in} LE(1-p_{in})}{1-Lp_{in} 1-LEp_{in}} \right] \frac{\rho}{f_-} (1-p_t)}{1 + \frac{1-LE}{1-LEp_{in} f_-} \rho (1-p_t(1-E))} \quad (3)$$

160

161 **TNCC Estimator Bias**

162 Across a wide range of self-reporting test-negative fractions (f_-), contact-tracing test-positive
163 fractions (p_t), participating fractions (p_{in}), and recruitment route ratios (ρ), the absolute error in \hat{E} is
164 ≤ 0.1 (Figure 2). If information from the outbreak response indicates these parameter values are
165 reasonable, then our model indicates study bias lies in that range. If that level of bias is not
166 acceptable, or if the study or outbreak parameters are outside of this range, we have identified two
167 avenues to limit bias, either restricting recruitment to participating or self-reporting individuals only.

168 **Restricting Recruitment to Participating Individuals**

169 Ideally, a study would achieve high participation in the recruitable population. This may be possible
170 if community engagement increases participation, or if there is additional data collected that allows

171 exclusion of non-participants, though identification of these individuals may be difficult. Even if the
172 study is constrained to only participating individuals, *i.e.* so $p_{in} = 1$, some bias remains due to
173 recruitment of contact-traced individuals but it no longer depends on the vaccine coverage (see
174 Supplement Section S5.1). However, perfect participation is unlikely, and the bias is sensitive to
175 other factors even when participation is high (Figure 3).

176 If the participating fraction decreases, generally the magnitude of bias in the estimate increases. Bias
177 generally peaks when the true efficacy is around 50%, and goes to zero as efficacy goes to 0 or 100%.
178 Because initial cases are more likely to be non-participating individuals, contact-traced individuals
179 from those cases are biased towards non-participation as well. Thus, bias trends toward
180 overestimation as contact-traced individuals more frequently test positive. This can reverse for high
181 levels of contact-traced recruitment, when most contact-traced individuals are test-negative. All
182 other factors being equal, more coverage means more extreme bias as participating and non-
183 participating individuals diverge.

184 Restricting Recruitment to Self-Reported individuals

185 The bias can also be corrected by restricting recruitment to self-reported individuals only. If perfectly
186 achieved then the bias is 0 (see Supplement S5.2). However, while there is a clear need to track
187 cases during an outbreak response, there is less motivation to carefully monitor test-negatives. Thus,
188 it may be possible to distinguish testing routes for test-positives, but not for test-negatives. If that
189 applies, the resulting estimator bias is:

$$190 \quad E - \hat{E} = -(1 - E)E \left[\frac{(1-LE)R'' - L \frac{1-p_{in}}{1-Lp_{in}} (\lambda - R'')}{B(1-LEp_{in}) + (1-LE)(\lambda - R''(1-E))} \right] \quad (4)$$

191 Minimising, and ultimately eliminating bias in Equation (4) still depends on maximising p_{in} . One way
192 of achieving high p_{in} is excluding non-participants; this suggests a trade-off between precision and
193 bias; if the study invests the effort to exclude non-participants it may make sense to include contact-
194 traced recruits.

195 If contact-traced test-positives are excluded retrospectively, the resulting bias magnitude can be
196 lower even if contact-traced test-negatives are included due to misclassification (Figure 3 vs Figure
197 4). However, the direction of bias changes with changing participation rates: the neutral line falls at
198 higher contact-tracing test-positive fractions when participation decreases. The magnitude of bias at
199 the extremes of the contact-tracing test-positive fractions is driven largely by the amount of self-
200 reporting test-negatives. Other factors being equal, fewer self-reported test-negatives means a
201 lower self-reporting test-negative fraction (0.8 instead of 0.99) and higher recruitment route ratio
202 (0.3 instead of 0.1), both of which correspond to more extreme bias.

203 Quantifying Potential Bias from Outbreak Response Metrics

204 To quantify the range of bias for a study in DRC, we determined the plausible range of outbreak
205 response metrics and corresponding model parameters, where SR_+ was 100-150, CT_+ was 100-400,
206 SR_- was 6500-7000, and CT_- was 900-1200.

207 When restricting recruitment to participating individuals only, the bias in vaccine efficacy is less than
208 3% overestimation (Figure 5, left panel), but can increase up to >15% overestimate for high coverage
209 and low participation (Figure 5, right panel; 90% coverage, 40% participation). As more non-
210 participating individuals are included, increasing coverage increases bias, corresponding to the
211 increasing distinction in infection risk between participation groups. For these outbreak response
212 metrics, the estimate of vaccine efficacy consistently exceeds the true efficacy.

213 When restricting recruitment to self-reported individuals only, with no misclassification of testing
214 route for test-negatives, the bias is 0 (Figure 6, left panel). As the misclassification rate increases
215 from 0 to 100%, the bias increases and tends toward underestimation, though the range of possible
216 bias includes overestimation. For the most extreme case, including all of contact-traced test-
217 negatives for a low participation fraction and a high-coverage, the bias spans roughly 1%
218 overestimate to 5% underestimate (Figure 6, right panel; 90% coverage, 40% participation). As with
219 restricting recruitment to participating individuals, the magnitude of the bias increases with
220 coverage amongst participating individuals.

221 Discussion

222 Previous work has explored biases in TNCC studies due to care-seeking or other confounding and
223 selection effects (35, 40, 41), test or vaccine status misclassification errors (25, 42-44), and vaccine
224 mechanism (36, 45). We demonstrated that the particular epidemiology of an outbreak can also
225 generate bias in the vaccine efficacy estimates in a TNCC study. If a study cannot distinguish self-
226 reported and contact-traced recruits or whether recruits were generally amongst a vaccinating
227 group, then the vaccine efficacy estimate is potentially biased. These are both real, practical
228 problems: in addition to general difficulty of collecting data during an outbreak, it may be difficult to
229 achieve uniform levels of vaccine coverage when rolling out a vaccine in an emergency setting,
230 particularly in highly mobile populations or those affected by civil unrest.

231 The bias in our model arises from the interaction of heterogeneous vaccination distribution and the
232 inclusion of tested individuals from contact-tracing. Because initial cases found through self-
233 reporting are more likely to be non-participating individuals (and thus non-vaccinating), including
234 contact-traced recruits overrepresents those individuals in the estimator. This in turn can tilt the bias
235 either towards or away from null, depending on how infection risk and testing criteria in the contact-
236 traced individuals differs from that in the general population. If the self-reporting process leads to
237 many more test-negative recruits than recruits from contact-tracing (either positive or negative),
238 then the bias from contact-tracing is relatively smaller. If it does not, then the relative number of
239 cases versus controls from contact-tracing will determine the general direction of bias; more cases
240 will lead to overestimation, more controls to underestimation.

241 We showed that the range of potential bias can be quantified with some epidemiological data from
242 the outbreak. For the range of outbreak response metrics we used to represent the EVD outbreak in
243 DRC, this is less than 10% if the study can achieve high participation ($p_{in} \geq 0.6$) with moderate
244 coverage ($L \leq 0.7$).

245 Practically, it may be possible to limit but not eliminate these drivers of the bias. For the EVD
246 epidemic in eastern DRC, responders try to test individuals that meet one of the outbreak
247 “suspected case” definitions, which combine different levels of symptoms and potential contact with
248 known cases (37, 38). This practice would likely continue in populations that received a study
249 vaccine, meaning this testing process would be the likely source for a retrospective TNCC study of a
250 new vaccine.

251 We framed our analysis in terms of event counts, but it can also be thought of in terms of testing
252 thresholds. For example, we frame contact-tracing recruitment as a number of contacts and the
253 number of cases amongst them, and the resulting efficacy estimator error is driven by the ratio of
254 those values. In an infectious disease sense, this ratio is the transmission probability, but it could
255 instead be interpreted as precision of the criteria for testing (*i.e.* positive-predictive value): are the
256 alert criteria such that we test fewer contacts and a larger percentage are positive (higher precision)
257 or do we test more frequently to ensure no positives are missed (lower precision)? A similar analogy

258 applies for testing outside contact-tracing. During an outbreak, the response may prefer less
259 stringent testing criteria to ensure as many cases as possible are identified to aid control. For both
260 the self-reported and contact-traced testing, the vaccine efficacy estimate bias is generally lower
261 when testing criteria are less stringent in this sense, consistent with a control-oriented outbreak
262 response.

263 Our analysis describes vaccination during EVD outbreaks, but our work has general implications for
264 evaluating interventions in other outbreak settings. We have focused on self-reporting and contact-
265 tracing, but the challenges are generic when there are distinct but potentially indistinguishable
266 primary and secondary recruiting processes. For example, more active general-population
267 surveillance could still qualify as the primary recruitment in our model, as long as it was random with
268 respect to intervention status. Likewise, geographic follow-up could be a secondary process, as long
269 as intervention status was correlated with the secondary process (*e.g.* for dengue, adjacent
270 households followed up, as long as vector control reached some areas and not others).

271 This analysis of the TNCC design under outbreak conditions does not consider other possible sources
272 of bias, such as different exposure risk between groups, testing errors, errors in ascertaining vaccine
273 status especially when there may be multiple vaccines or a long period between vaccination and
274 exposure, or other data problems that could occur. Further investigation of the reliability of TNCC
275 studies for vaccine efficacy estimation during outbreaks remains critical. However, as we have
276 shown, use of this design in an outbreak setting will need to account for the realities of control
277 activities, and plan to collect data on testing route or otherwise accommodate the mix of
278 recruitment routes.

279 Adoption of a TNCC design to evaluate a new vaccine in DRC may increase pressure for similar
280 studies that do not have an explicit, randomised control group in future outbreaks of similarly highly
281 pathogenic diseases. Understanding the biases and limitations of the TNCC design will therefore be
282 critical to evaluate vaccines that are currently being developed against these pathogens.

283 [Acknowledgements](#)

284 We thank Peter G. Smith and Nick Jewell for useful discussions during the development of this
285 model and analysis.

286 This work was supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking between
287 European Union Horizon 2020 Research and Innovation Programme and the European Federation of
288 Pharmaceutical Industries and Associations [EBOVAC3: grant number 800176]; Department of
289 Health and Social Care using UK Aid funding managed by the NIHR [VEEPED: PR-OD-1017-20007];
290 National Institutes of Health, National Institute of General Medical Sciences [U54 GM111274]; and
291 HDR UK Innovation Fellowship [grant MR/S003975/1 to R.M.E.]. The views expressed in this
292 publication are those of the authors and not necessarily those of the Department of Health and
293 Social Care.

294 [References](#)

- 295 1. Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations for
296 designing and interpreting intervention trials in infectious diseases. *BMC Med.* 2017;15(1):223.
- 297 2. Bellan SE, Eggo RM, Gsell P-S, Kucharski AJ, Dean NE, Donohue R, et al. An online decision
298 tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. *Vaccine.*
299 2019;37(31):4376 - 81.

- 300 3. Dean NE, Gsell P-S, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, et al.
301 Considerations for the design of vaccine efficacy trials during public health emergencies. *bioRxiv*.
302 2018.
- 303 4. Baden LR, Rubin EJ, Morrissey S, Farrar JJ, Drazen JM. We Can Do Better - Improving
304 Outcomes in the Midst of an Emergency. *N Engl J Med*. 2017;377(15):1482-4.
- 305 5. WHO. Vaccination in acute humanitarian emergencies: a framework for decision making.
306 2017.
- 307 6. Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical
308 considerations for vaccination programmes in acute humanitarian emergencies. *Bull World Health*
309 *Organ*. 2013;91(4):290-7.
- 310 7. Hatchett R, Lurie N. Outbreak response as an essential component of vaccine development.
311 *The Lancet Infectious Diseases*. 2019;19(11):e399-e403.
- 312 8. Owada K, Eckmanns T, Kamara KB, Olu OO. Epidemiological Data Management during an
313 Outbreak of Ebola Virus Disease: Key Issues and Observations from Sierra Leone. *Front Public Health*.
314 2016;4:163.
- 315 9. Kieny MP, Salama P. WHO R&D Blueprint: a global coordination mechanism for R&D
316 preparedness. *The Lancet*. 2017;389(10088):2469 - 70.
- 317 10. Hofman M, Au S. The politics of fear: *Medecins sans frontieres and the West African Ebola*
318 *epidemic*: Oxford University Press; 2017.
- 319 11. Beavogui AH, Delamou A, Yansane ML, Konde MK, Diallo AA, Aboulhab J, et al. Clinical
320 research during the Ebola virus disease outbreak in Guinea: Lessons learned and ways forward. *Clin*
321 *Trials*. 2016;13(1):73-8.
- 322 12. Mehand MS, Al-Shorbaji F, Millett P, Murgue B. The WHO R&D Blueprint: 2018 review of
323 emerging infectious diseases requiring urgent research and development efforts. *Antiviral Res*.
324 2018;159:63-7.
- 325 13. Kupferschmidt K. Plan to use second Ebola vaccine sparks debate. *Science*.
326 2019;364(6447):1221-.
- 327 14. Independent Ebola vaccination committee is needed to overcome lack of WHO transparency
328 [press release]. *Medecins Sans Frontieres*, 23-09-2019.
- 329 15. Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy J-F, et al. Randomised
330 controlled trials for Ebola: practical and ethical issues. *The Lancet*. 2014;384(9952):1423-4.
- 331 16. Consortium EçSRVT. The ring vaccination trial: a novel cluster randomised controlled trial
332 design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to
333 Ebola. *BMJ (Clinical research ed)*. 2015;351:h3740.
- 334 17. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al.
335 Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results
336 from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). *The Lancet*.
337 2017;389(10068):505 - 18.
- 338 18. Vaccine against Ebola: Commission grants first-ever market authorisation [press release].
339 European Commission, 11 November 2019.
- 340 19. First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical
341 milestone in public health preparedness and response [press release]. FDA, 19 December 2019.
- 342 20. WHO. Weekly epidemiological record. World Health Organization; 2019. p. 261–80.
- 343 21. SAGE. Strategic Advisory Group of Experts (SAGE) on Immunization Interim
344 Recommendations on Vaccination against Ebola Virus Disease (EVD). World Health Organization
345 (WHO); 2019.
- 346 22. Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen’s
347 Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo
348 (DRC) [press release]. 2019.
- 349 23. Vandebosch A, Mogg R, Goeyvaerts N, Truyers C, Greenwood B, Watson-Jones D, et al.
350 Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus

- 351 disease infection: Statistical considerations, design rationale, and challenges. *Clin Trials*.
352 2016;13(1):57-65.
- 353 24. ECBS ECOBS. Guidelines on the quality, safety and efficacy of Ebola vaccines. WHO Technical
354 Report Series. 2017;68:87-179.
- 355 25. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza
356 vaccine effectiveness: a systematic review. *Expert Rev Vaccines*. 2014;13(12):1571-91.
- 357 26. Araki K, Hara M, Shimano C, Nishida Y, Matsuo M, Tanaka K. Case-Control Study of
358 Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls. *J*
359 *Epidemiol*. 2019;29(8):282-7.
- 360 27. Walker JL, Andrews NJ, Atchison CJ, Collins S, Allen DJ, Ramsay ME, et al. Effectiveness of
361 oral rotavirus vaccination in England against rotavirus-confirmed and all-cause acute gastroenteritis.
362 *Vaccine X*. 2019;1:100005.
- 363 28. Haber M, Lopman BA, Tate JE, Shi M, Parashar UD. A comparison of the test-negative and
364 traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine
365 effectiveness. *Vaccine*. 2018;36(33):5071-6.
- 366 29. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination:
367 an alternative method to estimate the efficacy of pneumococcal vaccine. *N Engl J Med*.
368 1980;303(10):549-52.
- 369 30. Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, et al. The use of test-negative
370 controls to monitor vaccine effectiveness: a systematic review of methodology. *Epidemiology*. 2019.
- 371 31. Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, et al. Effectiveness of EV-A71 vaccination in
372 prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection
373 requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. *The Lancet*
374 *Child & Adolescent Health*. 2019;3(10):697-704.
- 375 32. Yung CF, Chan SP, Thein TL, Chai SC, Leo YS. Epidemiological risk factors for adult dengue in
376 Singapore: an 8-year nested test negative case control study. *BMC Infect Dis*. 2016;16:323.
- 377 33. Anders KL, Cutcher Z, Kleinschmidt I, Donnelly CA, Ferguson NM, Indriani C, et al. Cluster-
378 Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of
379 Community-Level Dengue Interventions. *Am J Epidemiol*. 2018;187(9):2021-8.
- 380 34. Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. The AWED trial
381 (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected mosquito
382 deployments to reduce dengue incidence in Yogyakarta, Indonesia: study protocol for a cluster
383 randomised controlled trial. *Trials*. 2018;19(1):302.
- 384 35. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the
385 effectiveness of influenza vaccine. *Vaccine*. 2013;31(30):3104-9.
- 386 36. Dean NE. RE: "MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE
387 DESIGN". *American Journal of Epidemiology*. 2019;188(4):806–10.
- 388 37. WHO. Case definition recommendations for Ebola or Marburg virus diseases. WHO; 2014.
- 389 38. WHO. Implementation and management of contact tracing for Ebola virus disease. WHO;
390 2015.
- 391 39. WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring
392 vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an
393 example of integration of research into epidemic response. 2019.
- 394 40. Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine
395 effectiveness from test-negative studies. *Vaccine*. 2017;35(52):7297-301.
- 396 41. Ferdinands JM, Foppa IM, Fry AM, Flannery BL, Belongia EA, Jackson ML. Re: "Invited
397 Commentary: Beware the Test-Negative Design". *Am J Epidemiol*. 2017;185(7):613.
- 398 42. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic
399 issues regarding the use of three observational study designs to assess influenza vaccine
400 effectiveness. *Int J Epidemiol*. 2007;36(3):623-31.

- 401 43. Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational
402 studies of influenza vaccine effectiveness. *Vaccine*. 2015;33(11):1313-6.
- 403 44. De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to
404 differential and non-differential disease- and exposure misclassification in studies of vaccine
405 effectiveness. *PLoS One*. 2018;13(6):e0199180.
- 406 45. Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine Direct Effects
407 Under the Test-Negative Design. *American Journal of Epidemiology*. 2018;187(12):2686–97.
- 408
- 409

410 Tables

411 Table 1: Definitions of terms used in this analysis.


Term	Definition
Recruitable population	The total population who may later be <i>recruited</i> into the <i>study</i> .
Vaccination campaign	Administration of the <i>target vaccine</i> to some of the <i>recruitable population</i> .
Study	A TNCC study of the <i>target vaccine</i> against EVD in the <i>recruitable population</i> .
Participating	The individuals in the <i>recruitable population</i> who could be vaccinated, with vaccination homogeneously distributed. <i>Non-participating</i> refers to the complementary portion of the <i>recruitable population</i> : none of these individuals receive the vaccine.
Recruitment	Testing for potential EVD infection and being counted in the <i>study</i> ; distinct from <i>participating</i> (in <i>vaccination</i>). Occurs via two routes: <i>self-reporting</i> and <i>contact-tracing</i> .
Self-reporting	Testing of individuals without a known link to a previous case.
Contact-tracing	Testing of individuals who have an association with a confirmed EVD case.

412 **Table 2: Parameter Summary.** This table summarizes the measurements and model parameters used in this
 413 analysis. We also introduce an alternative parameterization of the recruitment model, which is less intuitive
 414 when describing the model but more useful for understanding the impact on bias.

Vaccination Parameters			
Symbol	Name	Description	Calculation
E	True vaccine efficacy	The probability of preventing disease given an EVD exposure	Estimation target
\hat{E}	Estimated vaccine efficacy		Estimator, Equations 1-3
p_{in}	participating fraction	The fraction of the recruitable population with some vaccine coverage; the <i>non-participating fraction</i> , $1-p_{in}$, has no vaccine coverage	<i>see Supplement Section S7</i>
L	vaccine coverage	Among participating individuals, the achieved vaccine coverage	<i>see Supplement Section S7</i>
Outbreak Response Metrics			
SR ₊	Self-reported test-positive	Total number of individuals who test positive when they self-report to a health centre	Estimated from outbreak response metrics if available, either before or after start of vaccine campaign
SR ₋	Self-reported test-negative	Number who test negative when they self-report to a health centre	
CT ₊	Contact-traced test-positive	Number who test positive after identification by contact-tracing from a known case	
CT ₋	Contact-traced test-negative	Number who test negative after identification by contact-tracing from a known case	
Recruitment Parameters			
B	Self-reporting test-negative rate	The expected number of self-reporting test-negatives per self-reporting test-positive case	$\frac{SR_-}{SR_+}$
λ	Contact-tracing test rate	The expected number of tested contacts per self-reporting test-positive case	$\frac{CT_+ + CT_-}{SR_+}$
R''	Contact-tracing test-positive rate	The expected number of new infections amongst tested contacts of a known case, when the study vaccine is not present, per self-reporting test-positive case	$\frac{CT_+}{SR_+}$
Alternative Recruitment Parameters			
f_-	Self-reporting test-negative fraction	The proportion of self-reporting individuals that test-negative	$\frac{B}{B+1}$ or $\frac{SR_-}{SR_+ + SR_-}$
ρ	Recruitment route ratio	The ratio of contact-tracing recruitment to self-reporting recruitment	$\frac{\lambda}{B+1}$ or $\frac{CT_+ + CT_-}{SR_+ + SR_-}$
p_t	Contact-tracing test-positive fraction	The test-positive fraction of direct contact-tracing recruitment in the absence of vaccination	$\frac{R''}{\lambda}$ or $\frac{CT_+}{CT_+ + CT_-}$

415


416 Figures



417

418 **Figure 1. The modelled population and recruitment into the TNCC study.** (a) Individuals and their contacts
 419 either participate in vaccination (filled circles) or do not (open circles). (b) The fraction that participate (and
 420 thus may be vaccinated) is p_{in} . Of those that participate, some are not vaccinated (e.g. because they are
 421 ineligible) (light blue) and some are vaccinated (dark blue). The vaccine coverage in participants is L . In the
 422 recruitable population, non-vaccinees are infected on EVD exposure, while vaccinees avoid disease at the
 423 vaccine efficacy, E . (c) An expected number of self-reported people test negative, B , until a test-positive is
 424 identified. This leads to an expected amount of follow-up testing, λ , which finds R'' more cases if the initial
 425 case is non-participating, and $(1-LE)R''$ if participating. The coverage, L , efficacy, E , and participating fraction,
 426 p_{in} , determine the likelihood of observing the self-reporting case among participating vs non-participating
 427 individuals and vaccinated vs unvaccinated individuals. (d) Resulting categories that can be recruited into the
 428 study.


429



430

431 **Figure 2: Bias Trends Across All Model Parameters.** The figure illustrates the bias trends with respect to true
 432 efficacy, E , and vaccination coverage among participating individuals, L . The sixteen panels correspond to
 433 combinations of example values for: (outer columns) self-reporting test-negative fraction (f_- at low = 0.8 and
 434 high = 0.99); (inner columns) the recruitment route ratio (ρ at low = 0.5 and high = 2; less than 1 implies more
 435 self-reporting recruitment, greater than 1 implies more contact-tracing recruitment); (outer rows) contact-
 436 tracing test-positive fraction (p_t at low = 0.1 and high = 0.3); and the participating fraction (p_{in} , at low = 0.6 and
 437 high = 0.9).


438



439

440 **Figure 3: Impact of Decreasing Participating Fraction Amongst Recruits.** The panels show decreasing
 441 participation fraction (columns from left to right) for scenarios stratified by self-reported test-negative fraction
 442 in recruitment (0.8 and 0.99) and recruitment route ratio (0.1 and 0.3) (rows). This figure shows 70% coverage
 443 level among participating individuals, $L=0.7$.

444




445

446 **Figure 4: Bias Due to Inability to Exclude Contact-Traced Test-Negatives.** The panels show decreasing
 447 participation fraction (columns from left to right) for scenarios stratified by self-reported test-negative fraction
 448 in recruitment (0.8 and 0.99) and recruitment route ratio (0.1 and 0.3) (rows). This figure shows 70% coverage
 449 level among participating individuals, $L=0.7$. The range of bias is usually smaller than when recruitment is
 450 restricted to the participating individuals only (Figure 3).

451


452



453

454 **Figure 5: Bias possible when recruiting participating individuals only.** These bias envelopes were computed
 455 assuming outbreak response metrics $SR_- \in (6500, 7000)$, $SR_+ \in (100, 150)$, $CT_+ \in (100, 400)$, and $CT_- \in$
 456 $(900, 1200)$, which corresponds to 97.7-98.6% of self-reporting cases testing negative, testing 6-16 contact-
 457 traced individuals per self-reported case, and 10-25% of those contact-traced individuals testing positive. If the
 458 study is restricted to recruit only the participating individuals (left-most panel), then bias can be limited to less
 459 than 3% overestimation. However, as the participating fraction falls, the error range generally increases, to
 460 >15% peak bias for high coverage (90%) and low participation (40%). Higher coverage among participating
 461 individuals generally increases bias; this reflects increasing differences between the participating and non-
 462 participating individuals.

463



464

465 **Figure 6: Bias possible when recruitment is restricted to self-reported individuals only.** If the study analysis is
 466 able to restrict recruits to only self-reporting individuals, then there is no bias (left panel). However, as
 467 contact-traced test-negative individuals are increasingly included (moving right across panels), bias range
 468 increases to between 1% overestimate and 5% underestimate. However, this range is notably smaller than if
 469 only restricting to participating recruits (Figure 5). As with restricting recruitment to participating individuals
 470 only, higher levels of coverage lead to wider bias range. These ranges reflect the same parameters used in
 471 Figure 5, including participating fraction $p_{in} \in (0.4, 1)$.